Finn
IDXX Animal health diagnostics · Diagnostics · Pet care · Recurring revenue · Thesis updated November 8, 2026

Pet testing volume powers through falling clinic visits

01 Running thesis

Strong tests offset softer visits

IDEXX has a strong setup because vet clinics keep using its tests once its machines and software are placed inside the practice. That makes a large part of sales repeatable. In Q3 2026, overall organic revenue grew 10 percent, led by an 11 percent organic gain in CAG Diagnostics recurring revenue. This maintained an 1,100 basis point growth premium over U.S. clinic visits.

The inVue Dx launch remains a major growth driver. IDEXX placed over 1,900 inVue Dx analyzers in Q3 and is tracking to exceed its 5,500 full-year target. New catalysts are approaching quickly, including the rollout of fine-needle aspirate capabilities and the planned reveal of the MultiCue Dx platform at the upcoming VMX event.

The bear case centers on macroeconomic pressure. U.S. clinic visits declined 1.8 percent in Q3. While IDEXX outperformed this drop through higher prices and increased test utilization, prolonged weakness in vet visits could eventually limit top-line growth if owners delay non-essential care.

Nov 2026▲Q3 2026 earnings showed resilience with CAG Diagnostics recurring revenue growing 11 percent organically, keeping an 1,100 basis point premium over declining U.S. clinic visits. The company placed over 1,900 inVue Dx analyzers and acquired CoVet.
Aug 2026▲Q2 2026 results reinforced the bull case. CAG Diagnostics recurring revenue grew 10.3 percent organically despite a 1.3 percent drop in U.S. clinical visits, and the company placed 1,600 inVue Dx units.
May 2026▲Q1 2026 beat expectations and management raised full-year revenue and EPS guidance. CAG Diagnostics recurring revenue grew 11.0 percent organically, and the 2026 guide for that metric moved to 8.7 percent to 10.7 percent organic growth.
May 2026▲The Q1 2026 filing showed 15.4 percent organic growth in VetLab consumables and 28.0 percent organic growth in CAG instrument revenue. The filing also showed no new material risk factor changes.
Feb 2026→The 2025 Form 10-K confirmed the same core story. inVue Dx was launched in late 2024, CAG recurring revenue kept growing, and lower clinic visits remained a headwind.
Feb 2026▲IDEXX finished 2025 with about 6,400 inVue Dx placements, above the prior 6,000 target. Initial 2026 guidance called for 5,500 more inVue Dx placements and 8 percent to 10 percent organic growth in CAG Diagnostics recurring revenue.
Nov 2025▲Q3 2025 showed strong demand for inVue Dx, with more than 1,750 placements in the quarter. Management lifted its 2025 placement target to about 6,000 units.
02 Business model

Machines seed repeat testing

IDEXX operates a classic razor and blades business. The company places diagnostic machines in vet clinics. Then it sells the single-use tests, reference lab services, and software that clinics use repeatedly.

This model builds stickiness. A clinic that uses IDEXX instruments, reference labs, and practice software has to change complex workflows to switch vendors. That helps retention and gives IDEXX room to raise prices when the value is clear.

The model can face pressure if clinics run fewer tests per visit, delay new instrument purchases, or shift to a cheaper rival. It can also slow if a new platform gets placed but consumable use per machine takes longer than expected to build.

03 Product portfolio

Tests at the clinic and the lab

Growth engine

Point-of-care veterinary diagnostics

This includes Catalyst, ProCyte, inVue Dx, MultiCue Dx, and related consumables. The instruments seed future test use inside the clinic.

Cash cow

VetLab consumables

These are the single-use test materials used on IDEXX machines. They provide a highly profitable, recurring revenue stream.

Cash cow

Reference laboratory services

IDEXX runs labs that handle tests a clinic does not run in-house. The Cancer Dx panel is expanding to include hemangiosarcoma detection.

Steady

Veterinary software and imaging

Products like ezyVet, Neo, and the new CoVet AI workflow software help clinics run records, billing, and tasks.

Steady

Water testing

This business sells products that test water for microbes. Q3 2026 Water revenue grew 8 percent organically.

Steady

Livestock, Poultry and Dairy diagnostics

This segment sells tests used for herd, flock, and milk safety. Q3 2026 LPD revenue grew 3 percent organically.

Option

OPTI Medical and other

This is a small human medical diagnostics and out-licensing bucket. It is too small to drive the main thesis.

04 Business segments

Mostly companion animal care

Companion Animal Group92%growing fast
Water4%modest
Livestock, Poultry and Dairy3%modest
Other0%declining

Segment mix is based on Q1 2026 revenue. The Companion Animal Group remains the dominant driver, making this mostly a bet on pet diagnostics and vet clinic demand.

05 Risk factors

What could go wrong

Clinic visits keep falling

High impact · Medium odds

IDEXX can grow even when visits slip, but there is a limit. U.S. clinic visits fell 1.8 percent in Q3 2026. A deeper drop would pressure test volumes and make raised guidance harder to hit.

We watchU.S. same-store clinical visit growth compared to the company's assumptions.

Consumable pull-through slows

Medium impact · Medium odds

Placing machines is only the first step. The better business comes when clinics use the machines often and buy more consumables. The speed of revenue lift from new fine-needle aspirate use cases is an open question.

We watchVetLab consumables growth and management comments on inVue Dx consumable use per instrument.

Instrument growth faces tough comparisons

Medium impact · High odds

Instrument revenue surged earlier in the year, helped by heavy inVue Dx placements. That creates a high hurdle for the upcoming quarters as the company laps the early launch surge.

We watchCAG Diagnostics capital instrument revenue growth each quarter.

Global costs and currency move against it

Medium impact · Medium odds

IDEXX sells around the world and buys through global supply chains. Currency moves, tariffs, shipping delays, or higher input costs can hurt reported growth or margins.

We watchCurrency impact on revenue growth, gross margin movement, and comments on tariffs or shipping limits.
06 Quick answers

In one breath

How does IDEXX make most of its money?

Most revenue comes from the Companion Animal Group. The key stream is recurring diagnostics revenue, such as VetLab consumables, reference lab services, and related clinic software.

Why is inVue Dx important for IDEXX?

inVue Dx is a newer point-of-care analyzer for cytology and blood cell testing. Each placement can add future consumable sales, which is why the full-year placement target of 5,500 matters.

What is the biggest risk for IDXX stock?

The biggest business risk is that pet owners pull back on vet visits and testing. The stock also needs IDEXX to keep proving that growth can stay strong while clinic visits are still down.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. IDEXX Q2 2026 Form 10-Q
  2. IDEXX Q3 2026 earnings transcript
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near IDEXX Laboratories, Inc. in Finn's Diagnostics & Research industry ranking.

Get started with Finn today